DE60227492D1 - Hemmstoffe der akt aktivität - Google Patents

Hemmstoffe der akt aktivität

Info

Publication number
DE60227492D1
DE60227492D1 DE60227492T DE60227492T DE60227492D1 DE 60227492 D1 DE60227492 D1 DE 60227492D1 DE 60227492 T DE60227492 T DE 60227492T DE 60227492 T DE60227492 T DE 60227492T DE 60227492 D1 DE60227492 D1 DE 60227492D1
Authority
DE
Germany
Prior art keywords
ingredients
compounds
activity
act activity
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60227492T
Other languages
English (en)
Inventor
Stanley F Barnett
Samuel L Graham
David C Remy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60227492D1 publication Critical patent/DE60227492D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60227492T 2001-04-10 2002-04-08 Hemmstoffe der akt aktivität Expired - Lifetime DE60227492D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28278101P 2001-04-10 2001-04-10
PCT/US2002/011064 WO2002083138A1 (en) 2001-04-10 2002-04-08 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
DE60227492D1 true DE60227492D1 (de) 2008-08-21

Family

ID=23083087

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60227492T Expired - Lifetime DE60227492D1 (de) 2001-04-10 2002-04-08 Hemmstoffe der akt aktivität

Country Status (8)

Country Link
US (1) US7034026B2 (de)
EP (1) EP1379251B1 (de)
JP (1) JP4361276B2 (de)
AT (1) ATE400274T1 (de)
AU (1) AU2002252614B2 (de)
CA (1) CA2442270C (de)
DE (1) DE60227492D1 (de)
WO (1) WO2002083138A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
AU2003223467B2 (en) * 2002-04-08 2007-10-04 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
EP1558586B1 (de) * 2002-10-30 2011-03-30 Merck Sharp & Dohme Corp. Hemmer der akt aktivität
JP4693420B2 (ja) * 2003-04-18 2011-06-01 株式会社半導体エネルギー研究所 キノキサリン誘導体，及びそれを用いた有機半導体素子、電界発光素子及び電子機器
EP1622616B1 (de) * 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Hemmer der akt aktivität
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
WO2004096129A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
DE602004023838D1 (de) * 2003-04-24 2009-12-10 Merck & Co Inc Hemmer der akt aktivität
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
CN1942465A (zh) * 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
EP1737861A4 (de) * 2004-04-09 2010-04-28 Merck Sharp & Dohme Hemmer der akt aktivität
US7544677B2 (en) * 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
PT1898903E (pt) 2005-06-10 2013-06-28 Merck Sharp & Dohme Inibidores da atividade de akt
KR101540037B1 (ko) * 2005-09-12 2015-07-29 가부시키가이샤 한도오따이 에네루기 켄큐쇼 퀴녹살린 유도체, 및 퀴녹살린 유도체를 사용한 발광소자, 발광장치, 전자 기기
US20090062302A1 (en) 2006-01-24 2009-03-05 Buser-Doepner Carolyn A Jak2 Tyrosine Kinase Inhibition
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2004616B1 (de) 2006-03-21 2014-05-21 Semiconductor Energy Laboratory Co., Ltd. Chinoxalinderivat und lichtemittierendes element, lichtemittierendes gerät, elektronisches gerät, bei dem das chinoxalinderivat verwendet wird
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
CA2670767A1 (en) * 2006-12-06 2008-06-12 Merck & Co., Inc. Inhibitors of akt activity
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
EP2109608B1 (de) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer
US8178216B2 (en) * 2007-02-28 2012-05-15 Semiconductor Energy Laboratory Co., Ltd. Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
CN101754965B (zh) 2007-05-21 2014-03-19 诺华股份有限公司 Csf-1r抑制剂、组合物及使用方法
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP5574598B2 (ja) * 2007-12-03 2014-08-20 株式会社半導体エネルギー研究所 キノキサリン誘導体、およびキノキサリン誘導体を用いた発光素子、発光装置、電子機器
EP2067778B1 (de) * 2007-12-03 2016-08-17 Semiconductor Energy Laboratory Co., Ltd. Quinoxalin-Derivat und lichtemittierendes Element, lichtemittierende Vorrichtung und elektronische Vorrichtung damit
WO2009148887A1 (en) * 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
EP2303269B1 (de) * 2008-06-03 2014-07-30 Merck Sharp & Dohme Corp. Hemmer der akt-aktivität
US20110288090A1 (en) * 2009-02-02 2011-11-24 Armstrong Donna J Inhibitors of AKT Activity
JP2012517448A (ja) * 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
US8168652B2 (en) 2009-03-12 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
EP2488028B1 (de) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
CN102858767B (zh) 2009-12-17 2015-08-19 默沙东公司 作为syk抑制剂的氨基嘧啶
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
KR102072631B1 (ko) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140046059A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Process for the preparation of morpholino sulfonyl indole derivatives
EP2548877A1 (de) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Gliedrige kondensierte Pyridinyl)benzamide als BTK-Inhibitoren
WO2013032951A1 (en) 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
JP6093768B2 (ja) 2011-09-14 2017-03-08 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
WO2013043935A1 (en) 2011-09-21 2013-03-28 Neupharma, Inc. Certain chemical entites, compositions, and methods
WO2013049701A1 (en) 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2863915B1 (de) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. Substituierte diazin- und triazin-milz-tyrosinkinase-hemmer
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2916838B1 (de) 2012-11-12 2019-03-13 Neupharma, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014114185A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
CA2900303A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3082809B1 (de) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk-hemmer
US9834554B2 (en) 2013-12-20 2017-12-05 Merck Sharp & Dohme Corp. BTK inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2016106628A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106629A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US11840535B2 (en) 2018-07-02 2023-12-12 Shenzhen Targetrx, Inc. Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity
CN110272426B (zh) 2018-07-17 2022-05-31 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN109518211B (zh) * 2019-01-08 2020-11-06 合肥工业大学 一种芳香偶酰类化合物的电化学合成方法
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1384713A (fr) 1962-11-24 1965-01-08 Kalle Ag Matériel d'électrophotographie
NL300539A (de) * 1962-11-24
DE3420039A1 (de) * 1984-05-29 1985-12-12 Hoechst Ag, 6230 Frankfurt 2,3-bis(dialkylaminophenyl)chinoxaline und ihre verwendung in elektrophotographischen aufzeichnungsmaterialien
IN166761B (de) 1987-04-10 1990-07-14 Hoechst India
JPS6457261A (en) 1987-08-28 1989-03-03 Alps Electric Co Ltd Photoconductive film and electrophotographic sensitive body using same
EP0397859A4 (en) 1987-11-12 1990-12-19 Terumo Kabushiki Kaisha Pyrazine derivatives and medicinal preparation containing same
GB2293380A (en) 1994-09-22 1996-03-27 Zeneca Ltd Pesticidal heterocyclic and phenyl compounds
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
AU1918299A (en) 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
JP2000309578A (ja) 1999-04-27 2000-11-07 Kyowa Hakko Kogyo Co Ltd キノキサリン誘導体
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors

Also Published As

Publication number Publication date
US20040143117A1 (en) 2004-07-22
CA2442270C (en) 2009-09-08
US7034026B2 (en) 2006-04-25
EP1379251A4 (de) 2005-05-25
AU2002252614B2 (en) 2006-09-14
EP1379251B1 (de) 2008-07-09
ATE400274T1 (de) 2008-07-15
JP2004525961A (ja) 2004-08-26
EP1379251A1 (de) 2004-01-14
JP4361276B2 (ja) 2009-11-11
CA2442270A1 (en) 2002-10-24
WO2002083138A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
DE60227492D1 (de) Hemmstoffe der akt aktivität
CA2480800A1 (en) Inhibitors of akt activity
WO2003086279A3 (en) Inhibitors of akt activity
DE602004023838D1 (de) Hemmer der akt aktivität
ATE512957T1 (de) Hemmer der akt aktivität
DE602004026047D1 (de) Hemmer der akt aktivität
ATE503483T1 (de) Hemmer der akt aktivität
WO2002083675A3 (en) Inhibitors of akt activity
WO2006036395A3 (en) Inhibitors of akt activity
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
IS6658A (is) Ný efnasambönd
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
PT1263725E (pt) Novos compostos
YU84603A (sh) Novi inhibitori tirozin kinaze
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
ES2243579T3 (es) Derivados de pirazolopirideno.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
EA200100140A1 (ru) Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами
DE60201074D1 (en) Pyrazolopyridinderivate
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
SE9904128D0 (sv) Novel compounds
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

8328 Change in the person/name/address of the agent

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LUXEMBOURG, LU

R081 Change of applicant/patentee

Ref document number: 1379251

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1379251

Country of ref document: EP

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

Effective date: 20121213